Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Stamford-based Americares is partnering with Quest Diagnostics to provide 10 clinics across the U.S. with no-cost diagnostic services for one year as a means of increasing access to care for low-income, uninsured and underinsured patients.
Rutgers and Quest Diagnostics are expanding their collaboration to further improve access to critical primary care services for uninsured patients of the university’s Health Outreach Practice Experience (H.O.P.E.) Clinic in Plainfield. Resources from the Quest Diagnostics Foundation will enable the clinic to double its capacity by providing primary care services for a second day of the week.
Quest Diagnostics has secured breakthrough device designation for its adeno-associated virus (AAV) test, AAVrh74 ELISA assay, from the US Food and Drug Administration (FDA). The test is an enzyme-linked immunosorbent in vitro diagnostic assay intended for the semi-quantitative detection of antibodies (IgG) to AAVrh74 capsid in the serum of humans. Quest also expanded collaboration with Sarepta to develop complementary diagnostics for Sarepta's gene therapies.
Researchers from Quest Diagnostics and collaborators have found that changes in levels of the cardiovascular risk marker free myeloperoxidase (MPO) appear correlated with an individual's overall mortality risk. The finding, described in a study published last month in PLOS One, indicate that longitudinal measurement of MPO could help physicians assess patients' mortality risk and response to interventions.
Quest Diagnostics has partnered with Envision Sciences to commercially launch a novel prostate cancer biomarker test to help in identifying patients with more aggressive forms of the disease, Quest Diagnostics and the University of South Australia announced in separate news releases.1,2"Our goal for this innovative prostate biomarker test is to improve the accuracy of grading prostate cancer biopsies.
Made by New Jersey–based Quest Diagnostics, the $399 test can be purchased online by anyone age 18 and older in most US states, who then must go to a Quest clinic for a blood draw. The test measures blood levels of a protein called amyloid beta. As a person ages, amyloid beta tends to accumulate in the brain and can eventually form plaques, which are linked to Alzheimer’s disease. It’s thought that these clumps build up many years before memory loss and confusion appear.
For decades, employers have relied on workplace drug testing as a risk mitigation tool to effectively deter drug use and help prevent costly incidents. However, with cannabis legalization expanding, so is its use and acceptance. The connection between increasing cannabis availability and increased use of cannabis at work creates significant risks and costs for employers. So, why isn’t it possible to determine impairment from cannabis yet? “The main point many people fail to realize is that alcohol had decades, literally decades, of study to get to an impairment standard,” toxicology and workforce drug testing expert Barry Sample, of Quest Diagnostics, explains.
Quest Diagnostics launched on July 31 a direct-to-consumer blood test to detect abnormal levels of beta-amyloidTrusted Source, a protein involved in Alzheimer’s disease that can show up in the brain years before symptoms arise. The first-of-its-kind test, called AD-Detect, will cost $399, plus a $13 physician service fee. The technology is the same as the AD-Detect Amyloid Beta 42/40 Ratio blood test launched by the company in early 2022, which is available with a doctor’s order.
Laboratory operator Quest Diagnostics Inc beat estimates for quarterly profit on Wednesday, as people returned for regular checkups and tests that were delayed during a large part of the COVID-19 pandemic. Non-COVID testing at companies such as Quest and rival Labcorp was hit as people delayed routine health check-ups following pandemic-led lockdowns, but that demand has now started to normalize while COVID testing sales have fallen.
An analysis of 462 million lipid test results has shown mean total cholesterol levels exceed the target in seven of the 17 studied countries. Writing in the European Heart Journal, members of the Global Diagnostics Network (GDN) describe the evaluation of lipid test data generated by nine clinical laboratories working in 17 countries. Seth Martin, lead author of the study and professor of medicine at Johns Hopkins University School of Medicine, discussed the analysis and the potential implications of its findings in a statement from Quest Diagnostics, the company that leads the GDN.